SLU-PP-332 250mcg Capsules (100 ct)

Chemical Information:

• Molecular Formula: C₁₈H₁₄N₂O₂
• Molecular Weight: 290.32 g/mol
• Chemical Name: (E)-4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide
• CAS Number: 303760-60-3
• Molecular Structure: Refer to Certificate of Analysis for detailed structural information.

Description:
SLU-PP-332 is a novel synthetic small molecule extensively studied for its role as an estrogen-related receptor (ERR) pan-agonist, primarily targeting ERRα, ERRβ, and ERRγ. Research indicates its potential in modulating metabolic pathways, enhancing mitochondrial function, and promoting energy expenditure. Provided in tablet or capsule preparation specifically for advanced laboratory research in metabolism, energy regulation, and cellular bioenergetics.

Research Applications:
SLU-PP-332 is actively researched for potential roles in:

• Metabolic Regulation: Investigating effects on mitochondrial biogenesis, oxidative metabolism, and energy homeostasis.
• Exercise Mimetic Studies: Examining metabolic changes and enhanced endurance capacity mimicking physical exercise.
• Fatty Acid Metabolism: Studying its influence on fatty acid oxidation, energy expenditure, and metabolic rate modulation.
• Insulin Sensitivity Research: Exploring its impact on glucose uptake, insulin signaling pathways, and metabolic syndrome models.

Storage and Handling:

• Store tablets or capsules at controlled room temperature (15-25°C) in a dry, dark environment.
• Protect from moisture and direct exposure to sunlight.
• Handle with care, following laboratory best practices to maintain product integrity.

Product Specifications:

• Purity: ≥98% (HPLC Verified)
• Appearance: White to off-white solid tablets or capsules
• Solubility: Soluble in DMSO; limited solubility in aqueous solutions

Important Note:
This product is strictly FOR RESEARCH USE ONLY and is intended exclusively for in vitro research and laboratory experimentation by qualified professionals. It is not a drug, food, cosmetic, or dietary supplement, and has not been evaluated by the FDA. This compound is not intended to diagnose, treat, cure, or prevent any disease. The bodily introduction into humans or animals is strictly prohibited by law. Any misuse, misbranding, or mislabeling is a violation of federal regulations and may result in legal action under applicable federal, state, or local laws.

References:
Referenced scientific publications include:

• Kim, D. K., & Ryu, D. (2022). “Targeting ERRs in Metabolic Disorders: Opportunities and Challenges.” Trends in Pharmacological Sciences.
• Wang, Y., & Burris, T.P. (2022). “Nuclear receptor-based drug development for metabolic diseases.” Journal of Medicinal Chemistry.
• Gatto, G. J., et al. (2020). “Selective Activation of Estrogen-Related Receptor Alpha (ERRα).” Cell Chemical Biology.